Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 7, 2020

View Archived Issues

Angiopoietin-2 as diagnostic and prognostic biomarker in polymyalgia rheumatica

Phase II data presented for sevuparin in SCD patients with acute painful vaso-occlusive crisis

A novel retroviral murine model of anaplastic large cell lymphoma

MRT-252040 shows promising antileukemia activity in AML and DLBCL models

NRX-0492, a novel highly potent BTK degradation inducer

BR-001 shows promising preclinical activity in colon tumor models

Bacteria prevent host cell apoptosis

PD-1 blockade affects myeloid more than T cells

Samumed patents new Wnt signaling inhibitors

Reata Pharmaceuticals divulges RORC inverse agonists

Dana-Farber Cancer Institute presents EGFR and/or HER2 inhibitors

Bristol-Myers Squibb identifies Gal-3 inhibitors

Metacrine synthesizes new AOC3 inhibitors

Hepcidin mimetic PTG-300 begins phase II study in hereditary hemochromatosis

MRx-0518 begins new trial in combination with radiotherapy for resectable pancreatic cancer

Cytokinetics initiates phase II trial of CK-3773274 for hypertrophic cardiomyopathy

Mim8, an FVIII mimetic antibody, shows promise for hemophilia A

Oxurion reports phase I topline data on THR-687 for diabetic macular edema

TG-4050 enters first-in-human trials in head and neck cancer and ovarian cancer

Genentech begins phase II trial of BFKB-8488A in NASH

Lilly initiates phase I study of LY-3484356 in advanced or metastatic breast cancer

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 12, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 12, 2025.
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
ABS-1230 controls seizures in KCNT1-driven severe epilepsy
BioWorld Science
Mutations in the KCNT1 gene produce gain-of-function effects that lead to overactivation of the potassium channel and consequent disruption of normal neuronal...
CTAD 2025: The challenges of combination therapies for dementia
BioWorld Science
At the Clinical Trials on Alzheimer’s Disease 2025 meeting, a panel of experts discussed the need for developing combination therapies for the complex diseases...